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analysis of randomized trials
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Abstract
Background: Preterm birth is the principal factor contributing to adverse outcomes in multiple pregnancies.
Randomized controlled trials of progestogens to prevent preterm birth in twin pregnancies have shown no clear
benefits. However, individual studies have not had sufficient power to evaluate potential benefits in women at
particular high risk of early delivery (for example, women with a previous preterm birth or short cervix) or to
determine adverse effects for rare outcomes such as intrauterine death.
Methods/design: We propose an individual participant data meta-analysis of high quality randomized, double-
blind, placebo-controlled trials of progestogen treatment in women with a twin pregnancy. The primary outcome
will be adverse perinatal outcome (a composite measure of perinatal mortality and significant neonatal morbidity).
Missing data will be imputed within each original study, before data of the individual studies are pooled. The
effects of 17-hydroxyprogesterone caproate or vaginal progesterone treatment in women with twin pregnancies
will be estimated by means of a random effects log-binomial model. Analyses will be adjusted for variables used in
stratified randomization as appropriate. Pre-specified subgroup analysis will be performed to explore the effect of
progestogen treatment in high-risk groups.
Discussion: Combining individual patient data from different randomized trials has potential to provide valuable,
clinically useful information regarding the benefits and potential harms of progestogens in women with twin
pregnancy overall and in relevant subgroups.
Background
Preterm birth in twins
Preterm birth in multiple pregnancies is a major public
health concern. Stillbirths and neonatal deaths in twins
are 3 and 6 times higher than in singletons and a dis-
proportionate amount of long-term morbidity is asso-
ciated with multiple pregnancies [1]. Preterm birth is
the principal factor contributing to these adverse out-
comes, with 50% of twin pregnancies delivering before
37 weeks and 9% delivering before 32 weeks [2].
Improving outcomes in multiple pregnancies is a goal of
modern obstetrics, but as yet, few interventions have
been proven to be of benefit in this group. Thirty-three
to 56% of preterm births in twins are due to sponta-
neous preterm labor, making the prevention of preterm
labor an attractive strategy [2,3].
Progestogens to prevent preterm birth
Randomized trials in singleton pregnancies have sug-
gested that antenatal progestogens (including vaginal
progesterone and synthetic progestogens such as 17-
hydroyprogesterone caproate [17-OHPC]) prevents
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preterm delivery in women who are at high risk of pre-
term delivery because of a previous preterm delivery
[4,5] or a short cervix [6]. These trials have led investi-
gators to examine whether antenatal progestogens could
decrease preterm birth in multiple pregnancies.
Six randomized controlled trials of progestogens to
prevent preterm birth in twin pregnancies have now
been published, two large trials from the USA [7,8] and
one from the UK [9] and three smaller trials from Tur-
key [10], the UK [6] and the USA [11]. These studies
randomized women to either 17-OHPC/vaginal proges-
terone pessary, and placebo. One study, which included
67 women with twin pregnancies, 100 mg of vaginal
progesterone was found to reduce delivery before 37
weeks gestation (OR 3.48 [1.2-10.5]) [10]. In all other
studies [6,9,7], treatment with 17-OHPC or vaginal pro-
gesterone did not lead to any significant reduction in
preterm delivery or fetal loss. In the two largest trials,
however, a non-significant increase in intrauterine death
was seen in the treatment group [8,9]. Furthermore,
there was found a significant difference in median gesta-
tional age favoring placebo, in the other large trial [7].
We are aware of five other trials of progestogens in
multiple pregnancy that are nearing completion or pub-
lication [12-16]. In total these trials have included 3,522
women and more than 7,000 infants. Combining data
from these high-quality clinical trials has potential to
provide valuable information regarding the benefits and
potential harms of progestogens.
Rationale for an IPD meta-analysis
Aggregated data meta-analysis involves synthesis of esti-
mates from clinical trials. This allows for a more robust
estimate of the overall treatment effect of progestogen
on multiple pregnancies as well as a more conclusive
evaluation of any harmful effects. This is particularly
important, as two published RCTs of progestogens in
twins have shown a non-significant trend for increased
intrauterine death with progestogen treatment [8,9]. A
potential problem in aggregated data meta-analyses is
that primary outcomes of clinical trials as well as sub-
groups defined in clinical trials can differ, which makes
it impossible to pool the results of different studies. An
Individual participant data (IPD) meta-analysis over-
comes this problem as it involves synthesis of individual
level data from clinical trials. This allows for the same
robust estimate of the treatment effect and harmful
effects as in aggregated data meta-analysis, only now
more flexibility is possible regarding the choice of end-
points, subgroups and potential harms.
Performing an IPD meta-analysis as opposed to an
aggregated data meta-analysis has further advantages.
Firstly, IPD allows standardization of inclusion and exclu-
sion criteria and analysis across studies, independent of
bias that may arise through selective reporting [17]. Sec-
ondly, IPD allows for exploration of a differential treat-
ment effect in relevant subgroups (i.e. treatment
covariate interactions), for example, women with a
monochorionic twin pregnancy and women with a short
cervix [18]. Since IPD meta-analyses include more
detailed data on a patient level than aggregated data
meta-analyses, statistical power to carry out informative
subgroup analyses is higher. Furthermore, flexibility of
subgroup analyses is enhanced, thus the estimated sub-
group effects may be less influenced by misclassification
and bias. IPD meta-analysis therefore allows for a valid
assessment of differences in treatment effects across sub-
groups [19]. Thirdly, IPD allows time-to-event analysis.
Conventional meta-analysis only allows a pooled estimate
of treatment effect at specified cut-points, i.e. delivery
before 32, 34 or 37 weeks. The combined analysis of indi-
vidual data however, can take account of the time
between the initiation of treatment and the outcome of
interest [20]. This allows time-to-delivery analysis with
the construction of Kaplan-Meier analysis and the perfor-
mance of Cox regression. This means associations
between the timing and duration of progestogen treat-
ment and preterm birth and intrauterine death can be
explored. This is important because most published trials
have reported a non-significant trend towards a shorter
duration of pregnancy after the use of progestogens in
women with a multiple pregnancy [8,9,21,22].
Methods/designs
Criteria for inclusion of studies in IPD
We propose an IPD meta-analysis of randomized con-
trolled trials of 17- OHPC or vaginal progesterone ver-
sus placebo in women with twin pregnancies.
Participants
Inclusion criteria will be women with twin pregnancies,
with chorionicity and gestation confirmed by ultrasound,
who were included in a RCT comparing progestogens
with placebo for the prevention of preterm birth.
Women with congenital abnormalities, contraindications
to progestogen treatment and cervical cerclage will be
excluded.
Although studies have been performed in women with
triplet pregnancies [12,21,22] these will not be included in
the IPD meta-analysis. There appear to be differences in
the response to progestogens in women with singleton
and twin pregnancies, therefore further differences might
be anticipated between women with twins and those with
higher order multiples. As the number of trial participants
with triplet pregnancies is comparatively small compared
to the number with twin pregnancies, excluding these
women should not negatively affect the power of the
meta-analysis, whilst ensuring the group is as homogenous
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as possible. Exclusion of triplet pregnancies from the ana-
lyses will not compromise the validity of the study since
randomization was stratified for twin or higher order mul-
tiple in the studies that included both twin and triplet
pregnancies [7,8,12,21,22].
Intervention
The intervention will be either weekly intramuscular
injection of 17-hydroxyprogesterone caproate (17-
OHPC) or daily vaginal progesterone. As these treat-
ments may act differently and have different distribution
profiles we will analyze the results of the two types of
treatment separately.
Outcome measures
The primary outcome will be adverse perinatal outcome,
a composite outcome of perinatal death, defined as
death before discharge from the hospital, and significant
neonatal morbidity at discharge, defined as one or more
of respiratory distress syndrome (RDS) requiring ventila-
tion for ≥ 24 hr, bronchopulmonary dysplasia (BPD),
intraventricular hemorrhage (IVH) grade III or IV), peri-
ventricular leucomalacia (PVL), necrotizing enterocolitis
(NEC) grade II or more) culture proven sepsis, retinopa-
thy of prematurity (ROP) requiring treatment.
Secondary outcomes will be intrauterine death < 32
weeks or preterm birth < 32 weeks; intrauterine death <
35 weeks or preterm birth < 35 weeks; intrauterine
death < 37 weeks or preterm birth < 37 weeks; intrau-
terine death; fetal loss < 28 weeks or early preterm birth
< 28 weeks gestation; time to delivery or death. If data
is detailed enough, preterm birth will be analyzed sepa-
rately for spontaneous preterm birth and indicated pre-
term birth.
Subgroup analyses
Subgroup analyses will be performed for the primary
outcome only, in the following groups
- each of ultrasonographically diagnosed monochorio-
nic and dichorionic twins
- women who completed ≥ 90% of treatment
- women with a cervical length < 25 mm on baseline
assessment (in studies where transvaginal cervical length
measurement was specified in protocol)
- women with a prior spontaneous preterm birth < 37
weeks
- ethnicity
- each dose of vaginal progesterone, e.g. ≤ 100 mg ver-
sus ≥ 200 mg.
Identification of studies
We will perform an electronic search of the Cochrane
Central Register of Controlled Trials (CENTRAL),
PubMed, MEDLINE and ClinicalTrials.gov for published
or registered randomized controlled trials including
women with twin pregnancy that were randomly allo-
cated to treatment with progestogens (including vaginal
progesterone and 17-hydroxyprogesterone caproate) or
placebo in the second or third trimester with the inten-
tion to prevent preterm birth. We will use the search
terms “preterm birth” AND ["progesterone” OR “17
hydroxyprogesterone caproate” OR “progestogen"] AND
["pregnancy multiple” OR “pregnancy twin"] AND “ran-
domized controlled trial” AND “human”.
Two review authors (ES and SS) will independently
assess inclusion criteria and study quality and risk of
bias. A third author (BWJM) will review studies in
which there is any disagreement about study quality.
Risks of bias will be assessed in all of the identified stu-
dies based on [23]:
- sequence generation (i.e. computer generated ran-
dom number, use of random number table or other
truly random process)
- allocation concealment (i.e. web-based or telephone
central randomization or consecutively numbered sealed
opaque envelopes)
- blinding for participants, study personnel and out-
come assessors
- Incomplete outcome data
- Selective outcome reporting
- Other sources of bias
In cases where study quality is not clear from trial
protocols or publications, then the authors will be con-
tacted for clarification.
The corresponding authors of eligible studies will be
approached to take part in the IPD meta-analysis. They
will be invited to take part if the study is complete and
data available by 1st July 2011.
Data quality will be independently assessed by two
review authors (ES and SS). A third author (BWJM) will
review data in which there is any disagreement about
quality. Only studies with adequate outcome data (<
10% participant attrition or exclusion, with full reporting
of reasons for withdrawals and protocol violations and
no imbalance in drop-outs across groups) and adequate
reporting (all of the study’s pre-specified outcomes and
all expected outcomes of interest made available) will be
included.
Analysis
Overall effects of each treatment (17-OHPC and vaginal
progesterone) in women with twin pregnancies will be
estimated in the pooled IPD. Descriptive comparisons
between studies will be conducted to assess between-
study differences. We assume the data to be missing at
random (MAR), therefore observed patient characteris-
tics will be used to impute missing data, by means of
multiple imputation [24]. Missing data will be imputed
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within each original study, before data of the individual
studies are pooled. Treatment effects will be estimated
by means of a random effects log-binomial model and,
hence, the measure of association is the risk ratio. The
presence of heterogeneity of outcomes across trials will
be assessed using the I2 measure [25]. Heterogeneity
across studies and dependency between data originating
from the same study will be taken into account by fit-
ting a random intercept for each original study. If neces-
sary, analyses will be adjusted for variables used in
stratified randomization. Furthermore, dependency
between children born from the same pregnancy will be
accounted for by means of generalized estimating equa-
tions (GEE) [26]. To investigate subgroup effects, the
treatment effects will also be estimated within strata
based on single subgrouping variables, as well as using
an interaction term in the regression model.
Time-to-delivery analysis will be performed with
Kaplan-Meier analysis and Cox proportional hazards
regression analysis. Again, dependency between data origi-
nating from the same study will be taken into account by
conducting a stratified analysis (stratified by study) [27].
We will perform subgroup analysis with pooled indivi-
dual datasets of women stratified by the pre-specified cri-
teria outlined above. Where available we will plot cervical
length against gestational age of cervical length measure-
ment. When differences in gestational age explain differ-
ences in length, we will apply standardization for
gestational age. Differences in cervical length between
the studies will also be explored. We will assess the
absolute value of cervical length (corrected for gestational
age differences) as well as the percentiles of cervical
length (5th, 10th and 25th) in each dataset. We will
assess interaction between the treatment effect of proges-
togens and cervical length, using both time to delivery
and the primary and secondary endpoints. To ensure that
subgroup effects are not confounded by between-trial dif-
ferences, dependency between data originating from the
same trial will be taken into account using a random
intercept for every study in the regression model [18].
Discussion
The proposed IPD meta-analysis is necessary to deter-
mine whether progestogen treatment in twin pregnancy
is beneficial or harmful. This is the first study that com-
bines data on the effect of progestogens in twins and
the proposed IPD methodology will maximize the
impact of results.
The protocol for the individual participant data meta-
analysis has been designed with input from the authors
of ten randomized controlled trials of progestogens in
women with twin pregnancies, many of which have
been published in high impact factor journals (Table 1).
All authors have committed to providing data if their
studies meet inclusion criteria. In total these trials have
included 3,498 women and almost 7,000 infants, allow-
ing the meta-analysis to explore effects of progestogens
on rare outcomes and in high-risk subgroups. We
anticipate it will provide definitive data synthesis guiding
clinical practice and future research in this area.
Table 1 Overview of the studies published by authors consulted when planning the IPD meta-analysis
Study Period N Intervention Primary outcome
Briery[11] 06/04-06/10 30 250 mg 17-OPHC or placebo delivery before 35 completed weeks’ of gestation
Cetingoz[10] 12/04-02/07 67 100 mg vaginal
progesterone or placebo
delivery before 37 weeks
Lim[12] 08/06-07/09 654 250 mg 17-OHPC in 1 mL
castor oil or placebo
composite outcome (Severe RDS, BPD, IVH grade III or worse, NEC, proven sepsis
or death before discharge)
Combs[7] 11/04-02/10 240 250 mg 17-OHPC or placebo composite outcome (RDS, Oxygen therapy at 28d, Neonatal sepsis, Pneumonia,
IVH grade III or worse, periventricular leukomalacia, NEC, retinopathy of
prematurity, asphyxia)
Nassar[13] 10/06-10/10 290 250 mg 17-OPHC or placebo frequency of delivery prior to completed 37 weeks of gestation (259 days)
Norman[9] 12/04-04/08 500 Vaginal progesterone gel 90
mg or placebo
delivery or intrauterine death before 34 weeks of gestation
Rode[14] 06/06-09/10 650 200 mg vaginal
progesterone of placebo
incidence of delivery < 34 weeks
Rouse[8] 04/04-02/06 661 250 mg 17-OHPC in 1 mL
castor oil or placebo
composite outcome (delivery or fetal death before 35 completed weeks of
gestation)
Rozenberg[15] 06/06-06/10 160 500 mg 17-OPHC or no
treatment
Interval between inclusion and delivery
Serra[16] 01/06-05/08 246 200 mg or 400 mg vaginal
progesterone or placebo
Preterm birth rate (< 37 weeks)
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